Effects of Probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia - Fukuoka Atherosclerosis Trial (FAST)
Effects of Probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia - Fukuoka Atherosclerosis Trial (FAST)
复制标题
DOI：
10.1016/s0735-1097(01)01783-1
复制
发表时间：
2002-02-20
影响因子：
24
通讯作者：
Hayashi, J
中科院分区：
文献类型：
--
作者：
Sawayama, Y;Shimizu, C;Hayashi, J
目的探讨降低血脂对日本福冈地区无症状高胆固醇血症患者颈动脉内中膜厚度(IMT)的影响。背景颈动脉粥样硬化是冠心病(CHD)患者发病率和死亡率的独立预测因子。方法将246例无症状高胆固醇血症患者(平均年龄66岁)随机分为普罗布考(500 mg/d，n=82)和普伐他汀(10 mg/d，n=83)两组，并进入对照组(n=1)。以颈总动脉内膜中层厚度变化为主要终点指标，以9次主要心血管事件发生率为次要指标。结果在两年时间里，血清低密度脂蛋白(LDL)。普伐他汀组(36%)、普罗布考组(29%)和对照组(12%)的胆固醇显著降低(分别为P<；0.0001、P<；0.0001和P<；0.05)。两年后，普罗布考和普伐他汀组IMT显著减少(分别为-13.9%和-13.9%，P<；0.01和P<；0.01)，而对照组IMT显著增厚(23.2%；P<；0.05)。普罗布考可降低IMT增高率，与其降低低密度脂蛋白或高密度脂蛋白胆固醇无关。普罗布考治疗组心脏事件发生率(2.4%)明显低于对照组(13.6%)(p=0.0136)。结论普罗布考可降低胆固醇水平，稳定斑块，从而降低高胆固醇血症患者心脏事件的发生率。(C)2002年，由美国心脏病学会提供。
OBJECTIVES This study investigated the effect of reducing serum lipids on carotid artery intima-media thickness (IMT) in asymptomatic patients with hypercholesterolemia from Fukuoka, Japan.BACKGROUND Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in patients with coronary heart disease (CHD).METHODS A total of 246 asymptomatic hypercholesterolemic patients (mean age 66 years) were randomized to receive either probucol (500 mg/day, n = 82) or pravastatin (10 mg/day, n = 83) or to enter a control group (diet alone, n = 1); they were followed for two years. The chan e in IMT in the common carotid artery was the primary end point measure, and the 9 incidence of major cardiovascular events was the secondary measure.RESULTS Over the two-year period, serum low-density lipoprotein (LDL.) cholesterol was significantly reduced in the pravastatin group (36%), the probucol group (29%) and the control group (12%) (p < 0.0001, p < 0.0001 and p < 0.05, respectively). After two years, the probucol and pravastatin groups showed a significant reduction in IMT (- 13.9% and - 13.9% and p < 0.01 and p < 0.01, respectively), but there was significant IMT thickening (23.2%; p < 0.05) in the control group. Probucol reduced the rate of IMT increase, independently of its reduction of LDL or high-density lipoprotein cholesterol. Moreover, there was a significantly lower incidence of cardiac events in the probucol group (2.4%) than in the control group (13.6%) (p = 0.0136).CONCLUSIONS Probucol reduced cholesterol levels and stabilized plaque, leading to a lower incidence of cardiac events in these hypercholesterolemic patients. (C) 2002 by the American College of Cardiology.